Sonelokimab not checked
MoonLake Immunotherapeutics AG · M1095
FollowEvery change as it happens, and a Monday email
Trials
5 active
14 in total · 9 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Arthritis, Psoriatic (3 trials), Hidradenitis Suppurativa
- Main trialPhase 3
- “This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.”In the company’s words, NCT06641076 on ClinicalTrials.gov
- Other names
- M1095
Other drugs for Arthritis, Psoriatic
- SHR0302Hengrui · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- ZasocitinibTakeda · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- TildrakizumabSun Pharma · Phase 3
Coming up3
- 4 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 4 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 13 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06768671
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 28 May 2026 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | |
| Phase 3Active, not recruiting | 4 Jan 2027 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | |
| Phase 3Enrolling by invitation | 4 Feb 2028 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | |
| Phase 3Enrolling by invitation | 13 Jun 2028 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 14 Aug 2025 | Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 2 Sep 2025 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 28 Sep 2026 | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) | |
| Phase 2Completed | 20 Jun 2019 | A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis | |
| Phase 2Completed | 9 May 2023 | Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa | |
| Phase 2Completed | 5 Sep 2023 | Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis | |
| Phase 1Completed | 1 Nov 2025 | An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector | |
| Phase 2Ended | not given | A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris | |
| Phase 2Ended | not given | A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis | |
| Phase 2Authorised | not given | A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026